A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 May 2013
At a glance
- Drugs Erlotinib (Primary) ; Linsitinib (Primary) ; Goserelin; Letrozole
- Indications Advanced breast cancer
- Focus Biomarker; Registrational; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Nov 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 Jun 2010 Status changed from not yet recruiting to recruiting as reported by Vanderbilt-Ingram Cancer Center record.